<?xml version="1.0" encoding="UTF-8"?>
<p>Vaccine development must account for safety measures, including immune‐related adverse events (irAE) that may result from vaccination. ADE leading to a cytokine storm is a hallmark of SARS‐CoV pathogenesis and disease severity,
 <xref rid="rmv2161-bib-0127" ref-type="ref">
  <sup>127</sup>
 </xref> and of dengue infection.
 <xref rid="rmv2161-bib-0109" ref-type="ref">
  <sup>109</sup>
 </xref> This may also be the case for SARS‐CoV‐2.
 <xref rid="rmv2161-bib-0028" ref-type="ref">
  <sup>28</sup>
 </xref> ADE has been suggested to be caused by pre‐existing, non‐neutralizing, low‐affinity antibodies,
 <xref rid="rmv2161-bib-0111" ref-type="ref">
  <sup>111</sup>
 </xref> along with neutralizing antibody
 <xref rid="rmv2161-bib-0128" ref-type="ref">
  <sup>128</sup>
 </xref>; therefore, the antigen design of a vaccine must ensure correct antigen conformation
 <xref rid="rmv2161-bib-0129" ref-type="ref">
  <sup>129</sup>
 </xref> or spike‐based subunit vaccines lacking the receptor binding domain (RBD).
 <xref rid="rmv2161-bib-0128" ref-type="ref">
  <sup>128</sup>
 </xref>
</p>
